Featured
-
-
-
Comment |
GPRC5D as a novel immunotherapeutic target in multiple myeloma
The development of modern immune-based therapies for multiple myeloma has expanded rapidly over the past several years, and GPRC5D has been identified as a viable immunotherapeutic target. Herein, we discuss data and provide future perspectives on GPRC5D-directed CAR T cells and bispecific antibodies for patients with relapsed and/or refractory multiple myeloma.
- Karthik Nath
- , Bruno A. Costa
- & Sham Mailankody
-
-
Review Article |
The clinical development of antibody–drug conjugates — lessons from leukaemia
Antibody–drug conjugates (ADCs) were originally developed for patients with haematological malignancies. In light of the recent increase in interest in this type of therapy, this Review describes the clinical experience with two ADCs — gemtuzumab ozogamicin and inotuzumab ozogamicin — in patients with haematological malignancies and provides guidance on the future directions for the development of novel ADCs for patients with leukaemias.
- Elias Jabbour
- , Shilpa Paul
- & Hagop Kantarjian
-
-
-
Review Article |
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Tyrosine kinase inhibitors (TKIs) are the most common agents used for the treatment of patients with chronic myeloid leukaemia (CML). Several agents are available for frontline treatment, or after the development of resistance or intolerance to agents previously used. Herein, the authors evaluate differences between available TKIs, and discuss several end points that can be considered when selecting the first and subsequent lines of treatment of patients with CML.
- Gianantonio Rosti
- , Fausto Castagnetti
- & Michele Baccarani
-
Review Article |
Modern approaches to HLA-haploidentical blood or marrow transplantation
In the past, only patients with fully HLA-matched donors were able to benefit from blood or bone-marrow transplantation (BMT) for a variety of haematological malignancies. Owing to the development of a variety of immunomodulatory strategies, patients with no HLA-matched donor, who can therefore receive an HLA-haploidentical BMT, can expect the same or similar outcomes as those receiving HLA-matched BMT. In this Review, the authors describe the new approaches to immunomodulation that have made HLA-haploidentical BMT a realistic therapeutic approach.
- Christopher G. Kanakry
- , Ephraim J. Fuchs
- & Leo Luznik
-
-
-
Review Article |
Advances in umbilical cord blood manipulation—from niche to bedside
The use of umbilical cord blood (UCB) as source of haematopoietic cell is becoming a mainstay treatment for several diseases. Its principal limitation is the low number of haematopoietic stem and progenitor cells (HSPC), which leads to prolonged engraftment times. The two main approaches to improve UCB engraftment have been to expand HSPCex vivobefore transplantation, or to augment HSPC homing. This Review focuses on approaches and clinical trials aimed at realizing these strategies.
- Troy C. Lund
- , Anthony E. Boitano
- & John E. Wagner
-
-
Research Highlight |
Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ALL
- David Killock
-
-
-
In Brief |
Ponatinib active in BCR–ABL-positive disease
-
-
-
-
Correspondence |
Alemtuzumab treatment for hemophagocytic lymphohistiocytosis
- Maciej Machaczka
- , Johan Vaktnäs
- & Yenan T. Bryceson
-
Case Study |
Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis
This Case Study describes a patient with multiple relapses of atypical HLH that became refractory to treatment with numerous immunosuppressive agents. As HLH is driven by CD52+T cells and histiocytes, alemtuzumab was used as targeted therapy to induce stable remission and enable allogeneic stem-cell transplantation to be successfully performed.
- Matthew P. Strout
- , Stuart Seropian
- & Nancy Berliner